<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073953</url>
  </required_header>
  <id_info>
    <org_study_id>PQ Study 3</org_study_id>
    <nct_id>NCT04073953</nct_id>
  </id_info>
  <brief_title>Primaquine Enantiomers in G6PD Deficient Human Volunteers</brief_title>
  <official_title>Metabolism and Pharmacokinetics of Primaquine Enantiomers in G6PD Deficient Human Volunteers Receiving a Five Day Dose Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi, Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Mississippi, Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will
      be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability
      of primaquine enantiomers and placebo over the course of 5 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will receive a 15 mg dose of one enantiomer (SPQ or RPQ or Placebo) daily for up
      to 5 days, with careful monitoring of hematological parameters before and after each dose. In
      addition to the general CMP14 safety criteria, any subject who displays a fractional
      hemoglobin drop of 15% below his/her baseline value, then drug administration will stop (e.g.
      for baseline Hgb of 14 g/dL, if there is at any point a decrease of 2.1 g/dL). Hematocrit
      will be similarly monitored, with proportional stop criteria. Elevation in total bilirubin to
      2.0 mg/dL or greater will also be used as a stopping criterion. After stopping drug
      administration (5 days or whenever stop criteria are met), subjects will have a 3-week
      washout period, and the study repeated with the other enantiomer, and similarly with Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Methemoglobin concentration in blood from baseline</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Change in Methemoglobin concentration in blood from baseline (% hemoglobin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primaquine Plasma Concentration, ng/mL</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Plasma concentrations of parent drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carboxy-Primaquine Plasma Contration, ng/mL</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Plasma concentrations of carboxy-primaquine metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primaquine N-carbamoyl-glucuronide Plasma contration, ng/mL</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Plasma concentrations of Primaquine N-carbamoyl-glucuronide metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primaquine Orthoquinone Plasma concentration, ng/mL</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Plasma concentrations of Primaquine Orthoquinone metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hematocrit (%) compared to baseline</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Change in Hematocrit (%) compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin (g/dL) compared to baseline</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Change in Hemoglobin (g/dL) compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change is AST (U/L) compared to baseline</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Change is AST (U/L) compared to baseline; used to monitor liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT (U/L) compared to baseline</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Change in ALT (U/L) compared to baseline; used to monitor liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total Bilirubin (mg/dL) compared to baseline</measure>
    <time_frame>Days 0, 3, 5</time_frame>
    <description>Change in total Bilirubin (mg/dL) compared to baseline; used to monitor liver function and red cell integrity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>G6PD Deficiency</condition>
  <arm_group>
    <arm_group_label>RPQ (-) enantiomer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will receive 15mg of RPQ every day for 5 days. Cohort 2 will receive 22.5 mg of RPQ every day for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPQ (+) enantiomer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1 will receive placebo capsules every day for 5 days. Cohort 2 will receive placebo capsules every day for five days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPQ</intervention_name>
    <description>The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.</description>
    <arm_group_label>RPQ (-) enantiomer</arm_group_label>
    <other_name>R-(-) Enantiomer of Primiquine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPQ</intervention_name>
    <description>The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.</description>
    <arm_group_label>SPQ (+) enantiomer</arm_group_label>
    <other_name>S-(+) Enantiomer of Primaquine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  G6PD deficient, otherwise normal healthy adults aged 18 to 65

        Exclusion Criteria:

          -  Known history of liver, kidney or hematological disease (other than G6PD deficiency)

          -  Known history of cardiac disease, non-sinus rhythm arrhythmia or QT prolongation

          -  Autoimmune disorders

          -  Report of an active infection

          -  Subject is pregnant or breast-feeding, or is expecting to conceive during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Walker, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Larry Walker, Ph.D.</last_name>
    <phone>662-915-1005</phone>
    <email>lwalker@olemiss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerri Harrison, RN</last_name>
    <phone>662-915-2103</phone>
    <email>laharri6@olemiss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>University</city>
        <state>Mississippi</state>
        <zip>38677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerri Harrison, RN</last_name>
      <phone>662-915-2103</phone>
      <email>kaharri6@olemiss.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>G6PD</keyword>
  <keyword>Hemolysis</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

